Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.

Author: DongMeichen, EvonDonna M, LokAnna S, MichaelLarry, NelsonDavid R, PeterJoy, ReeveBryce B, StewartPaul W

Paper Details 
Original Abstract of the Article :
The PRIORITIZE trial (clinicaltrials.gov: NCT02786537) was the first comparative effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic hepatitis C virus (HCV). A secondary aim of this study was to compare LDV/SOF and E...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/jvh.13716

データ提供:米国国立医学図書館(NLM)

Sustainable Relief in the Desert of Hepatitis C: A Comparative Study of Treatment Options

Hepatitis C, a viral infection that can cause liver damage and cirrhosis, is a complex condition that can feel like navigating a vast and unforgiving desert. Recent advancements in treatment have led to highly effective antiviral medications, but finding the most effective and sustainable option for patients remains a key challenge. This research directly compares two antiviral regimens, ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR), analyzing their impact on HCV-associated symptoms and functional well-being in patients who achieve sustained virological response (SVR).

A Oasis of Sustainable Relief

The researchers found that both LDV/SOF and EBR/GZR regimens demonstrated significant and durable improvements in HCV-associated symptoms and functional well-being, even up to two years after SVR. This is like finding a sustainable oasis in the desert, where resources are plentiful and can sustain life over time. The study's findings suggest that both regimens offer valuable treatment options for patients with chronic hepatitis C infection.

Hepatitis C: Navigating the Sands with Hope

Hepatitis C is a treatable condition, and there are effective treatment options available. However, it's essential to work closely with a hepatologist to determine the best regimen for your individual needs and circumstances. Remember, the desert of hepatitis C can be navigated with the right guidance and support, and there are oases of hope and healing waiting to be discovered.

Dr. Camel's Conclusion

This study highlights the transformative impact of effective antiviral therapy on the lives of patients with chronic hepatitis C. Both LDV/SOF and EBR/GZR offer sustainable relief from symptoms and improve functional well-being, creating a sense of hope and empowerment for those navigating the desert of this challenging condition. It's a reminder that with dedication and advancements in medical science, we can find oases of healing and restoration in the face of adversity.

Date :
  1. Date Completed 2022-08-11
  2. Date Revised 2022-10-23
Further Info :

Pubmed ID

35657133

DOI: Digital Object Identifier

10.1111/jvh.13716

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.